

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

WWW.FULBRIGHT.COM

TELEPHONE: 512-474-5201

FACSIMILE: 512-536-4696

Date: Thursday, December 20, 2001**No. of pages (including cover):** 12**Matter No.:** ARCD:307USD1/10100104**TO**

Examiner Delia Ramirez

Facsimile No.: (703) 308-0294

FROM

Gina N. Shishima

Phone No.: (512) 536-3081

User ID: 01985 Floor: 20

COMMENTS

If you experience any problems with this transmission or have questions, please call the sender.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address at our expense.

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
 600 CONGRESS AVENUE, SUITE 2400
 AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
 FACSIMILE: 512/536-4698

WRITER'S INTERNET ADDRESS:
 GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
 512/536-3081

HOUSTON
 WASHINGTON, D.C.
 AUSTIN
 SAN ANTONIO
 DALLAS
 NEW YORK
 LOS ANGELES
 MINNEAPOLIS
 LONDON
 HONG KONG

December 20, 2001


FILE: ARCD:307USD1

10100104

CERTIFICATE OF FACSIMILE TRANSMISSION
 37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted to: Assistant Commissioner for Patents,
 Washington, D.C. 20231, Attn: Examiner Della Ramirez,
 facsimile number (703) 308-0294 on the date below:

December 20, 2001
 Date


 Gina N. Shishima

Commissioner for Patents
 Washington, DC 20231

RE: SN 09/768,877 "METHODS OF TREATMENT OF TYPE 2 DIABETES" - by Polonsky
et al. (UTH:256)

Commissioner:

Enclosed for filing in the above-referenced patent application is a Supplemental Preliminary Amendment.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10100104/GNS.

Respectfully submitted,



Gina N. Shishima
 Reg. No. 45,104

:1b

Encl.: As stated